Focusing on drugs that appeared to reverse cancer-related gene expression signatures, researchers identified candidate compounds that thwarted cancer cell lines.
The PAM50 breast cancer classifier successfully split prostate cancer samples into luminal and basal subtypes with ties to patient outcomes and treatment response.
Researchers have identified several gene expression signatures that predict a patient's sensitivity to adjuvant chemotherapy. A test based on the findings could help identify which patients will do well with current treatments, and which might benefit from entering a clinical trial.
The researchers found that treatment with lactate and ketones causes cancer cells to express gene profiles associated with “stemness.” They believe that these gene signatures could, in turn, predict poor clinical outcome in breast cancer patients.
Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.
